Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 08, 2018

Adding Abiraterone or Docetaxel to Long-Term Hormone Therapy for Prostate Cancer

Annals of Oncology

 

Additional Info

Annals of Oncology
Adding Abiraterone or Docetaxel to Long-Term Hormone Therapy for Prostate Cancer: Directly Randomised Data From the STAMPEDE Multi-Arm, Multi-Stage Platform Protocol
Ann. Oncol 2018 Feb 26;[EPub Ahead of Print], MR Sydes, MR Spears, MD Mason

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading